Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarizotan for treatment-associated dyskinesia in Parkinson's disease (Phase III)
2004-001594-25Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) and dyskinesia comparing Sarizotan 1 mg b.i.d with Placebo (2 arms). Primary endpoint: Responder rate at 12 and 24 weeks based on UPDRS dyskinesia items. Started Oct 2004; status: completed.
02
Drugs
sarizotan
03
Conditions
Parkinson's disease (PD)dyskinesia
Beyond the preview
Go deeper on 2004-001594-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001594-25.